Schmer G, Branson H E
Br J Haematol. 1975 May;30(1):117-22. doi: 10.1111/j.1365-2141.1975.tb00524.x.
The caseinolytic activity of one CTA (Committe on Thrombolytic Agents) unit of human plasmin is inhibited by a series of plasma dilutions containing antiplasmin. Then neutralization of the standard plasmin by increasing amounts of antiplasmin shows a steeper linear decrease of plasmin activity betwwen 1.0 and 0.5 CTA units and a much smaller further inactivation below 0.5 CTA units. It is thought that the standard plasmin is partially damaged at the antiplasmin combining site during the purification procedrue and might be responsible for the differences in plasmin-antiplasmin neutralization in the standard curve. Using the steeper slope of the plasmin neutralization curve, an average of 8.6 +/- 1.0 CTA units plasmin neutralizing activity per ml human plasma was found in 36 healthy donors. The difficulty of obtaining 'native' standard plasmin with full antiplasmin combining capacity represents the main problem of a reproducible reliable antiplasmin assay.
一系列含有抗纤溶酶的血浆稀释液可抑制1个CTA（溶栓剂委员会）单位人纤溶酶的酪蛋白溶解活性。然后，通过增加抗纤溶酶的量来中和标准纤溶酶，结果显示，在1.0至0.5 CTA单位之间，纤溶酶活性呈更陡峭的线性下降，而在低于0.5 CTA单位时，进一步失活则小得多。据认为，标准纤溶酶在纯化过程中其抗纤溶酶结合位点受到部分损伤，这可能是标准曲线中纤溶酶 - 抗纤溶酶中和存在差异的原因。利用纤溶酶中和曲线较陡的斜率，在36名健康供体中发现，每毫升人血浆平均具有8.6±1.0 CTA单位的纤溶酶中和活性。获得具有完全抗纤溶酶结合能力的“天然”标准纤溶酶存在困难，这是可重复可靠的抗纤溶酶测定的主要问题。
